News - Neurological, Roche

Filter

Current filters:

NeurologicalRoche

Popular Filters

Xenon and Genentech establish new pain discovery collaboration

26-03-2014

Privately-held US biotech firm Xenon Pharmaceuticals has established a new collaboration with Swiss drug…

BiotechnologyGenentechLicensingNeurologicalResearchRocheXenon Pharmaceuticals

Prothena to get $30 million upfront from Roche triggered by regulatory milestone

Prothena to get $30 million upfront from Roche triggered by regulatory milestone

23-01-2014

Clinical-stage biotech firm Prothena said today that it will receive the $30 million upfront payment…

BiotechnologyFinancialLicensingNeurologicalProthenaPRX002Roche

Disappointing results for Roche in Phase III schizophrenia studies

Disappointing results for Roche in Phase III schizophrenia studies

21-01-2014

Swiss drug major Roche (ROG: SIX) has revealed disappointing results from two Phase III studies of its…

bitopertinNeurologicalNorthern EuropePharmaceuticalResearchRoche

Prothena inks deal with Roche, worth a potential $600 million

Prothena inks deal with Roche, worth a potential $600 million

12-12-2013

Biotech firm Prothena has entered into a worldwide collaboration with Swiss drug major Roche to develop…

BiotechnologyGlobalLicensingNeurologicalProthenaPRX002ResearchRoche

US nephrologists views on prescribing Roche’s Mircera

02-10-2013

Among surveyed US nephrologists, familiarity with Swiss drug major Roche's Mircera is low, but is still…

InjectaferKeryx BiopharmaceuticalsMirceraNeurologicalNorth AmericaPharmaceuticalRocheZerenex

US FDA backs news indications for Latuda; grants Priority Review for Perjeta

02-07-2013

Sunovion Pharmaceuticals, a US subsidiary of Japan's Dainippon Sumitomo Pharma (TYO: 4506), says that…

BiotechnologyDainippon Sumitomo PharmaLatudaNeurologicalNorth AmericaOncologyPerjetaPharmaceuticalRegulationRocheSunovion

Positive recommendations from EMA's CHMP for Selincro, Adasuve and Perjeta

17-12-2012

Last week's deliberations of the European Medicines Agency's Committee for Medicinal Products for Human…

AdasuveAlexza PharmaceuticalBiotechnologyEuropeFerrer InternacionalLundbeckNeurologicalOncologyPerjetaPharmaceuticalRegulationRocheSelincro

Roche and Lilly drugs chosen for major Washington University Alzheimer's prevention trial

11-10-2012

Leading scientists at the USA's Washington University at St Louis have selected the first drugs to be…

BiotechnologyEli LillygantenerumabNeurologicalPharmaceuticalResearchRochesolanezumab

Scotland denies access to Roche skin cancer drug Zelboraf, but OKs Novartis' Gilenya

11-09-2012

Swiss drug major Roche (ROG SIX) says it is "extremely disappointed" that the Scottish Medicines Consortium…

EuropeGilenyaHealthcareNeurologicalNovartisOncologyPharmaceuticalPricingRegulationRocheZelboraf

Roche returns rights to Biotie Therapies SYN120

27-06-2012

Finland-based Biotie Therapies (OMX: BTH1V) said yesterday that it is retaining global development and…

Biotie TherapiesLicensingNeurologicalPharmaceuticalRocheSYN120

Second collaboration in Alzheimer's disease for Genentech and AC Immune

18-06-2012

Switzerland-based biopharma company AC Immune said this morning that it has entered into a second exclusive…

AC ImmuneBiotechnologycrenezumabGenentechLicensingNeurologicalPharmaceuticalResearchRoche

Groundbreaking Alzheimer's prevention trial announced, as US debuts AD program

17-05-2012

A collaboration of the US National Institutes of Health (NIH), Banner Alzheimer's Institute (BAI), University…

crenezumabGenentechNeurologicalNorth AmericaPharmaceuticalPoliticsResearchRoche

UK NICE asks for more data on Tarceva, and Botox for migraine

17-02-2012

UK drug watchdog the National Institute for Health and Clinical Excellence (NICE) today issued new draft…

AllerganBotoxEuropeNeurologicalOncologyPharmaceuticalPricingRegulationRocheTarceva

Xenon in $646 million deal with Roche unit

10-01-2012

Canada based Xenon Pharmaceuticals, a privately-owned, clinical genetics-based drug discovery and development…

BiotechnologyGenentechLicensingNeurologicalPharmaceuticalResearchRocheXenon Pharmaceuticals

UK NICE says Novartis MS drug Gilenya not cost effective, but backs extended use of Roche’s MabThera

01-12-2011

In further draft guidance published today (December 1), UK drugs watchdog the National Institute for…

EuropeGilenyaMabTheraNeurologicalNovartisOncologyPharmaceuticalPricingRegulationRoche

Roche's MAb gantenerumab seen to remove amyloid plaques from the brain of Alzheimer’s patients

12-10-2011

Swiss drug major Roche (ROG: SIX) says that its monoclonal antibody gantenerumab removes amyloid plaques…

gantenerumabNeurologicalPharmaceuticalResearchRoche

Roche to pay Evotec up to $830 million for Alzheimer’s compound

06-09-2011

Swiss drug major Roche (ROG: SIX) has entered into an exclusive worldwide agreement with Germany’s…

EvotecLicensingNeurologicalPharmaceuticalRoche

Back to top